KMTS (Kestra Medical Technologies) Debt-to-Asset : 0.13 (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KMTS Kestra Medical Technologies Ltd KMTS
12 GF Score
Price $25.95
! 5 Warning Signs
View Full Analysis

What is Kestra Medical Technologies Debt-to-Asset?

Kestra Medical Technologies KMTS +8.09% 12 Debt-to-Asset is 0.13 as of Apr. 2026. GuruFocus rates KMTS with a GF Score™ of 12/100. The stock has 5 warning signs investors should review.

Kestra Medical Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2026 was $0.03 Mil. Kestra Medical Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2026 was $46.76 Mil. Kestra Medical Technologies's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Apr. 2026 was $358.47 Mil. Kestra Medical Technologies's debt to asset for the quarter that ended in Apr. 2026 was 0.13.

Kestra Medical Technologies  (NAS:KMTS) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Kestra Medical Technologies Debt-to-Asset Related Terms

Kestra Medical Technologies Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Kestra Medical Technologies's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kestra Medical Technologies Debt-to-Asset Chart

Kestra Medical Technologies Annual Data
Trend Apr20 Apr21 Apr23 Apr24 Apr25 Apr26
Debt-to-Asset
Get a 7-Day Free Trial 0.75 1.01 0.98 0.15 0.13

Kestra Medical Technologies Quarterly Data
Apr20 Jul20 Apr21 Jul21 Apr23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.17 0.18 0.12 0.13

KMTS vs AZTA, STAA, BLFS: Debt-to-Asset Comparison

For the Medical Instruments & Supplies subindustry, Kestra Medical Technologies's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kestra Medical Technologies Debt-to-Asset vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Kestra Medical Technologies's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Kestra Medical Technologies's Debt-to-Asset falls into.


KMTS
12GF Score
Kestra Medical Technologies Ltd KMTS
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kestra Medical Technologies Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Kestra Medical Technologies's Debt-to-Asset for the fiscal year that ended in Apr. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.031 + 46.76) / 358.465
=0.13

Kestra Medical Technologies's Debt-to-Asset for the quarter that ended in Apr. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.031 + 46.76) / 358.465
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.13 mean?
Kestra Medical Technologies (KMTS) has a Debt-to-Asset of 0.13 as of Apr. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Kestra Medical Technologies and its competitors.
Is Kestra Medical Technologies' Debt-to-Asset too high?
Kestra Medical Technologies' current Debt-to-Asset is 0.13. Overall, Kestra Medical Technologies has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kestra Medical Technologies' Debt-to-Asset compare to AZTA and STAA?
Kestra Medical Technologies' Debt-to-Asset of 0.13 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Medical Devices & Instruments company?
A good Debt-to-Asset depends on the Medical Devices & Instruments industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Kestra Medical Technologies and its competitors. Kestra Medical Technologies's current Debt-to-Asset is 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kestra Medical Technologies stock overvalued right now?
Kestra Medical Technologies (KMTS) has a current Debt-to-Asset of 0.13. The current Debt-to-Asset is 0.13. Kestra Medical Technologies' overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Kestra Medical Technologies (KMTS), the current Debt-to-Asset is 0.13 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kestra Medical Technologies Business Description

Address 3933 Lake Washington Boulevard NE, Suite 200, Kirkland, WA, USA, 98033
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
12GF Score

Get the complete analysis for KMTS

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.95
Price